Impact of TP53 mutations on EGFR-tyrosine kinase inhibitor efficacy and potential treatment strategy

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma

(2022) Natalie I. Vokes et al.   Journal of Thoracic Oncology

Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC—opportunities and obstacles

(2021) Brielle A. Parris et al.   Annals of Translational Medicine

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

(2021) Umair Majeed et al.   Journal of Hematology & Oncology

Correlation of tumor mutational burden (TMB) with CDKN2A and TP53 mutation in HPV-negative head and neck squamous cell carcinoma (HNSCC).

(2020) Barbara Burtness et al.   JOURNAL OF CLINICAL ONCOLOGY

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy

(2020) Yubo Wang et al.   LUNG CANCER

Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study

(2020) Masato Aragaki et al.   Journal of Cardiothoracic Surgery

Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site

(2020) Shuo Chen et al.   CANCER CELL

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors

(2020) Leilei Wu et al.   Frontiers in Oncology

Genomic Signature of Driver Genes Identified by Target Next‐Generation Sequencing in Chinese Non‐Small Cell Lung Cancer

(2019) Shiwang Wen et al.   ONCOLOGIST

Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients

(2019) Ran Xu et al.   MEDICINE

Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas

(2019) Lawrence A. Donehower et al.   Cell Reports

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC

(2019) Helei Hou et al.   Cancer Management and Research

Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes

(2018) Zheng Yang et al.   International Journal of Biological Sciences

Mutant p53 as a guardian of the cancer cell

(2018) Fiamma Mantovani et al.   CELL DEATH AND DIFFERENTIATION

TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database

(2018) Victor D. Li et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Mechanisms of DNA damage, repair, and mutagenesis

(2017) Nimrat Chatterjee et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes

(2017) Paul A. VanderLaan et al.   LUNG CANCER

Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine

(2017) Helei Hou et al.   Oncotarget

Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

(2016) Matteo Canale et al.   CLINICAL CANCER RESEARCH

The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement

(2013) L. C. Villaruz et al.   CLINICAL CANCER RESEARCH

Abstract 240: Functional impact of p53 hotspot mutantions on tumor development and therapy responses in the Eµ-myc mouse lymphoma model

(2012) Soyoung Lee et al.   CANCER RESEARCH

Interaction of the p53 DNA-Binding Domain with Its N-Terminal Extension Modulates the Stability of the p53 Tetramer

(2011) Eviatar Natan et al.   JOURNAL OF MOLECULAR BIOLOGY

Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know

(2010) Mizuki Nishino et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies

(2010) I Goldstein et al.   CANCER GENE THERAPY

Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway

(2009) Peixin Dong et al.   Molecular Cancer